A Multi-National Trial Evaluating Safety and Efficacy Including Pharmacokinetics, of NNC 0129-0000-1003 when Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A (Protocol No. NN7008-3859)

Service: Trial Number:
Principal Investigator: Conducted at:
Miller Children's & Women's Hospital Long Beach
Currently enrolling additional patients:
Age Range:
7-17 years; 18 years & up
Male & Female

This research study, called “Pathfinder 2” is conducted by Dr. Paula Groncy and her team at Miller Children’s Hospital Long Beach. The purpose of this research trial is to investigate the efficacy and the safety of a new experimental Factor VIII drug product called N8-GP. Factor VIII is one of the normal coagulation factors in the blood that helps the blood to stop bleeds by making a clot. Patients diagnosed with severe hemophilia A, with no signs of inhibitor development and are otherwise in good health, can participate in this study. The goal of this extension phase of the trial is to look at long term safety of N8-GP. Treatment can be given either as an injection on a regular basis to prevent bleeding episodes occurring and/or as treatment at the first signs of bleeding to stop the bleeding episode as quickly as possible.